SCHEMBL12199239

SCHEMBL12199239

OCCNC1=Nc2ccccc2SC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 2/20 0.47
KDM4E B2RXH2 5/20 0.38
MAPK1 P28482 1/20 0.38
ALDH1A1 P00352 4/20 0.35
POLB P06746 3/20 0.35
GAA P10253 3/20 0.35
RAB9A P51151 2/20 0.35
GLA P06280 2/20 0.35
LMNA P02545 2/20 0.35
MITF O75030 1/20 0.35
TTR P02766 1/20 0.35
RAD52 P43351 1/20 0.35
RECQL P46063 1/20 0.34
MCL1 Q07820 1/20 0.34
ADRA2A P08913 4/20 0.33
ADRA2B P18089 4/20 0.33
ADRA2C P18825 4/20 0.33
TSHR P16473 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2524058 0.78 OPRK1 (0.58) OPRK1ALDH1A1POLBGAARAB9A
SCHEMBL3015629 0.72 OPRK1 (0.50) OPRK1ALDH1A1POLBGAARAB9A
SCHEMBL3027026 0.72 KMT2A (0.49) OPRK1KDM4EALDH1A1GAALMNA
SCHEMBL13214832 0.71 OPRK1 (0.46) OPRK1ALDH1A1POLBGAARAB9A
SCHEMBL3022272 0.71 OPRK1 (0.43) OPRK1KDM4EALDH1A1GAARAB9A
SCHEMBL3023952 0.70 ALDH1A1 (0.50) OPRK1MAPK1ALDH1A1POLBGAA
SCHEMBL3010928 0.70 OPRK1 (0.45) OPRK1POLBRAB9ALMNAMEN1
SCHEMBL14676712 0.69 APOBEC3A (0.34) POLBSMN1; SMN2CYP3A4
SCHEMBL11336620 0.68 OPRK1 (0.49) OPRK1KDM4EALDH1A1POLBRAB9A
SCHEMBL9510450 0.66 OPRK1 (0.41) OPRK1KDM4EALDH1A1RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969577-B2 Curable composition comprising a thermolatent base BASF SE (DE) 2015-03-03 US disclosed
US-8969577-B2 Curable composition comprising a thermolatent base BASF SE (DE) 2015-03-03 US disclosed
EP-2367794-B1 CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE BASF SE (DE) 2013-01-09 EP disclosed
US-20110245375-A1 CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE BASF SE (DE) 2011-10-06 US disclosed
US-20110245375-A1 CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE BASF SE (DE) 2011-10-06 US disclosed
WO-2010057922-A1 CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE BASF SE (DE) 2010-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245375-A1 CURABLE COMPOSITION COMPRISING A THERMOLATENT BASE COIL, MAPT, ASH2L OPRK1 3706/4885KDM4E 1082/4885MAPK1 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.